Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?

As the reimbursement status for the cost of hospital-acquired infections is under pressure by payors, interest in preventing these complications at the outset is growing. Nosocomial vaccines offer one route of prevention. This report assesses the clinical pipeline candidates five key nosocomial pathogens and their potential market environment including target population size estimates.

Scope
In-depth analysis of epidemiology, spread, costs and reimbursement linked to nosocomial infections across the major Western markets

Thorough general and pathogen-specific assessment of the market potential for the major 5 classes of nosocomial vaccines

In-depth discussion and sizing estimates of potential target groups for nosocomial vaccines by pathogen

Review of alternative strategies for infection prevention and comparison with vaccination

Reasons to Purchase
Review the epidemiological, clinical and economical factors driving new product decisions in nosocomial vaccine development.

Gain insight into the pipeline through a discussion of key candidates in clinical development for five nosocomial pathogens.

Understand and identify key market opportunities by reviewing sizing estimates for key target populations by pathogen.